PL3641800T3 - Modulacja immunogenności fviii przez skrócony vwf - Google Patents

Modulacja immunogenności fviii przez skrócony vwf

Info

Publication number
PL3641800T3
PL3641800T3 PL18737505.0T PL18737505T PL3641800T3 PL 3641800 T3 PL3641800 T3 PL 3641800T3 PL 18737505 T PL18737505 T PL 18737505T PL 3641800 T3 PL3641800 T3 PL 3641800T3
Authority
PL
Poland
Prior art keywords
modulation
truncated vwf
fviii
immunogenicity
fviii immunogenicity
Prior art date
Application number
PL18737505.0T
Other languages
English (en)
Inventor
Anne VERHAGEN
Sabine Pestel
Thomas Weimer
Marco Hofmann
Huy Huynh
Eugene Maraskovsky
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Publication of PL3641800T3 publication Critical patent/PL3641800T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Soft Magnetic Materials (AREA)
  • Two-Way Televisions, Distribution Of Moving Picture Or The Like (AREA)
  • Medicinal Preparation (AREA)
PL18737505.0T 2017-06-22 2018-06-22 Modulacja immunogenności fviii przez skrócony vwf PL3641800T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17177477 2017-06-22
EP18153579 2018-01-26
PCT/EP2018/066696 WO2018234518A1 (en) 2017-06-22 2018-06-22 Modulation of fviii immunogenicity by truncated vwf

Publications (1)

Publication Number Publication Date
PL3641800T3 true PL3641800T3 (pl) 2024-03-18

Family

ID=62837861

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18737505.0T PL3641800T3 (pl) 2017-06-22 2018-06-22 Modulacja immunogenności fviii przez skrócony vwf

Country Status (12)

Country Link
US (1) US11141466B2 (pl)
EP (1) EP3641800B1 (pl)
JP (1) JP2020530436A (pl)
KR (1) KR20200018690A (pl)
CN (1) CN110799208A (pl)
AU (1) AU2018287215A1 (pl)
BR (1) BR112019026743A2 (pl)
CA (1) CA3068098A1 (pl)
DK (1) DK3641800T5 (pl)
ES (1) ES2966835T3 (pl)
PL (1) PL3641800T3 (pl)
WO (1) WO2018234518A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021001522A1 (en) * 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US20220348637A1 (en) * 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DE69534265T2 (de) 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
JP2010529155A (ja) 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用
PL2291523T3 (pl) 2008-06-24 2015-05-29 Csl Behring Gmbh Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
WO2011060242A2 (en) 2009-11-13 2011-05-19 Talecris Biotherapeutics, Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
WO2013093760A2 (en) 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
JP2015515482A (ja) 2012-04-24 2015-05-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
WO2013160005A1 (en) * 2012-04-24 2013-10-31 Novo Nordisk A/S Pharmaceutical composition suitable for treatment of haemophilia
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
CN105452289A (zh) 2013-06-12 2016-03-30 诺和诺德股份有限公司 适用于治疗血友病的化合物
AU2015270394B2 (en) 2014-06-06 2017-12-21 Octapharma Ag Preparation comprising Factor VIII and Von Willebrand factor peptides
BR112016030950A2 (pt) * 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
EP3297656B1 (en) 2015-05-22 2020-01-08 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
JP6651548B2 (ja) 2015-05-22 2020-02-19 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 改変フォン・ヴィルブランド因子を製造するための方法
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
DK3400002T3 (da) 2016-01-07 2022-04-11 CSL Behring Lengnau AG Muteret, trunkeret von willebrand faktor
US20190134166A1 (en) * 2016-04-12 2019-05-09 Propanc Pty Ltd Composition of proenzymes for cancer treatment

Also Published As

Publication number Publication date
EP3641800A1 (en) 2020-04-29
KR20200018690A (ko) 2020-02-19
EP3641800B1 (en) 2023-10-04
DK3641800T3 (da) 2024-01-02
JP2020530436A (ja) 2020-10-22
AU2018287215A1 (en) 2020-02-06
US11141466B2 (en) 2021-10-12
CA3068098A1 (en) 2018-12-27
WO2018234518A1 (en) 2018-12-27
DK3641800T5 (da) 2024-08-26
CN110799208A (zh) 2020-02-14
ES2966835T3 (es) 2024-04-24
BR112019026743A2 (pt) 2020-06-30
US20200197495A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
ZA201801035B (en) Vaccine compositions
IL258184A (en) Modulation of the immune system
PT3207053T (pt) Novos péptidos imunogénicos
GB201705765D0 (en) HBV vaccine
GB201711635D0 (en) Immunogenic composition
ZA201808246B (en) Improvement of hpv l2 peptide immunogenicity
GB201610599D0 (en) Immunogenic Composition
IL248223B (en) Compositions of vaccine
EP3164150A4 (en) Modified von willebrand factor
ZA202001561B (en) Human cytomegalovirus immunogenic composition
GB201802339D0 (en) Immunogenic composition
GB201711637D0 (en) Immunogenic composition
PL3641800T3 (pl) Modulacja immunogenności fviii przez skrócony vwf
GB201512906D0 (en) Fluoro-silicone compositions as temporary bonding adhesives field of the invention
GB201614485D0 (en) Immunogenic composition
GB201604755D0 (en) Immunogenic compositions
IL258295A (en) Fviii formulation
ZA201707503B (en) Her2/neu immunogenic composition
GB201703529D0 (en) Vaccine composition
GB201718251D0 (en) Vaccine Compositions
IL256199A (en) A preparation containing a combination of peptides
GB201415679D0 (en) Silk Protien Structures
TWM488892U (en) Multifunctional stereoscopic breathable insole
GB2564901B (en) Vaccine compositions
GB201718337D0 (en) Malaria vaccine